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Thyroid hormones (THs) are involved in the regulation of many physiological processes in vertebrates.
Competition for TH binding sites on serum transport proteins can interfere with delivery of THs to target tissues,
and this is a potential mechanism of action of exogenous thyroidogenic substances. To date, detailed accounts of
in vitromethods for competitive binding with THs on TH transport proteins (human or wildlife) are sparse. In the
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K.L. Hill et al. /MethodsX 4 (2017) 404–412 405descriptionswere brief andwith insufﬁcient details for successful replication. Furthermore, upon review of these
methodologies, we identiﬁed several opportunities for optimization. The present study addresses the
methodological deﬁciencies and describes, in detail, a fully optimized and validated competitive T4 radio-
ligand binding assay with human transthyretin (TTR) and albumin (ALB).
 Signiﬁcant improvements weremade over previousmethods, including bettermaintenance of protein stability
and enhanced measurement of competition between different ligands.
 Sample size was reduced to allow use of small pre-packed size exclusion chromatography columns, which
eliminates the rinsing step during the separation procedure.
 The assay was parameterized for use with T4 and human TTR and ALB.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Background
The structural resemblance of many anthropogenic chemicals to thyroid hormones (THs) warrants
concern for the perturbation of TH-dependent processes in humans and other vertebrates [1].
Thyroxine (T4) and 3,5,3-triiodothyronine (T3) are THs involved in the regulation of many important
physiological processes in the body including neurological and behavioural development, growth,
metabolism, and respiration [2]. In mammals (including humans), circulating T4 concentrations are
greater in plasma than for T3. T4 is the prohormone TH, and it is deiodinated via enzyme-controlled
mechanisms toT3, which is themain ligand for the TH receptor leading to gene regulation [3]. The vast
majority (>99%) of THs in plasma are delivered to target tissues by binding to TH transport proteins,
which include albumin (ALB), transthyretin (TTR), and thyroxine-binding globulin (TBG). The TH
binding afﬁnities and dissociation constants of these three proteins vary, with ALB having the lowest
relative afﬁnity for T4 and the greatest concentration in plasma; and TBG having the highest afﬁnity
for T4, and the lowest concentration in plasma [4]. TTR is the only TH transport protein synthesized in
the choroid plexus, and it thus plays a role in the movement of THs from the blood into the
cerebrospinal ﬂuid (CSF) which is particularly important in early development [3].
One potential mechanism of action of xenobiotic thyroidogenic substances is competition for TH
binding sites on serum transport proteins, as this can interfere with delivery of THs to target tissues. A
limited number of previously published studies report variations of the in vitro radiolabelled T4-TTR
binding assay technique, with target chemicals including polychlorinated biphenyls, perﬂuorinated
compounds, polybrominated diphenyl ethers, and some degradation products [1,5–10]. However, the
methods reported in these studies do not provide sufﬁcient details to successfully replicate the
procedure and we faced several challenges in attempting to do so. Therefore, the objectives of the
present study were to reﬁne, optimize, validate, and fully describe a competitive in vitro radio-ligand-
protein binding assay that is used to investigate thyroidogenicity of chemicals via interaction between
T4 and human TTR. Furthermore, we expanded this method to include interactions between T4 and
human ALB which, to our knowledge, has not been adequately described elsewhere. The model
xenobiotic chemical that we used as a competitor ligand is 4-hydroxy-2,20,4,50-tetrabromodiphenyl
ether (4-OH-BDE-49), which is often detected in human serum [11] and has previously been found to
bind to human TTR isolated from human plasma with higher afﬁnity than T4 in vitro [9].
A number of other methods have been developed for the purpose of investigating potential
competition of xenobioticswith T4 for TTR, including the ANSA (8-anilino-1-naphthalenesulfonic acid
ammonium)-TTR competitive ﬂuorescence displacement assay [12], the TR-CALUX (thyroid hormone
responsive chemically activated luciferase gene expression) assay [13], surface plasmon resonance-
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assays [15,16], and HPLC (high performance liquid chromatography) assays [17]. Notably, Ouyang et al.
[16] presents an enhanced FITC-T4 assay that has been miniaturized into a 96 well microplate to
generate a high throughput method. While the miniaturized FITC-T4 method offers increased
efﬁciency, the radiolabelled T4-protein binding assay described herein ismore sensitive than the assay
presented in Ouyang et al. [16], and by an order ofmagnitude for potent xenobiotic competitors (those
with IC50s<100nM). This is particularly important for the detection of receptor binding events at low
concentrations (e.g., those found in blood or other biological samples) and for reducing the likelihood
of a type II error. Additionally, our method extends to include interactions with ALB, which increases
the relevance of this assay as ALB is the most abundant protein in plasma and serum.
Sample preparation (Day 1)
The entire assay takes two days to complete for each batch of samples to be processed. The Day
1 procedure is described as follows. Prepare the solutions of the proteins, THs and competitive ligands
to be used in the in vitro assay according toTable 1 and using materials speciﬁed in Table 2. First, thaw
the working solutions of these components to room temperature if they have been placed in frozen
storage. For the proteinworking solutions, prepare the day they are to be used based on the number of
assay aliquots required (one vial is sufﬁcient for approximately 45 assay samples). Take note of the
protein handling recommendations in the Precautions and Tips section. Label a series of
polypropylene test tubes corresponding to the samples being prepared. This should include triplicate
samples for each ligand competitor concentration. See Fig. 1 for an example of [31_TD$DIFF]the sample set up for a
batch of assays including vial labels and contents.
Prepare the T4/125I-T4/Tris-EDTA buffer solution using one polypropylene test tube per triplicate
set of samples. For each, pipette 20mL of T4 working solution, 200mL [32_TD$DIFF]of 125I-T4 stock solution (see
Precautions and tips for details on signal strength required), and 2580mL of Tris-EDTA into the test
tube(s) and invert to mix (resulting in the addition of 0.5mL T4, 5mL 125I-T4, and 64.5mL Tris-EDTA to
each sample).
The following steps describe the order of pipetting components for assay incubation mixtures.1. Starting with the calibration curve samples (T4 as a competitor), pipette 5mL of the lowest
competitor concentration into all replicate assays. Continue for each increasing concentration of
the ligand. Control samples receive 5mL of DMSO in place of a competitor ligand.2. For the ﬁrst “replicate set” (e.g., 1.1–11.1 in Fig. 1), pipette 70mL of the T4/125I-T4 solution into each
test tube, followed by 25mL of the selected protein (e.g., TTR). This results in a total sample volume
of 100mL.3. Centrifuge the samples at 300 g for 30 s to force the solution to the bottom of the tube.
4. Measure the initial radioactivity on the gamma counter. Cap the samples immediately, being careful
not to disturb solutions, and place in the fridge at 4 C overnight [33_TD$DIFF]to reach protein-ligand binding
equilibrium.
While the ﬁrst replicate set is on the gamma counter, repeat Steps 2 to 4 for the subsequent
replicate set(s) (e.g., 1.2 to 11.3). Follow the same preparation sequence for the xenobiotic competitor
(s) being analyzed (e.g., 4-OH-BDE-49).
Separation procedure (Day 2)
Label a series of clean test tubes corresponding to the samples prepared on Day 1 and repeat
these labels on Bio-Spin1 columns. Work on one replicate set at a time, leaving the remaining
columns and incubation mixtures in the fridge until ready for processing. Prepare spin columns for
use according to Bio-Spin1 column instructions (invert column to re-suspend gel, remove cap and
tip, centrifuge in test tube at 1000 g for 2min, discard drained packing buffer). Process the
incubation mixtures as follows:
Table 1
Preparation and storage details for the stock and ﬁnal concentrations of the ligands and transport proteins for the thyroid hormone competitive binding assay.
Component Stock Solution Working Solution Final
Concentration
in Sample
Concentration Preparation Storage Concentration Preparation Volume Added
to Sample
Protein (Select One)
TTR 3.64mM Dissolve 0.5mg into 2500mL
Tris-EDTA by inversion and
portion into 40mL aliquots
1500mL polypropylene
microcentrifuge tubes
at 20 C for up to one
year
120nM Add 1160mL Tris-EDTA to aliquot on
day of use
25mL 30nM
ALB 72.8mM Dissolve 12.1mg into 2500mL
Tris-EDTA by inversion and
portion into 40mL aliquots
1500mL pp tubes at
20 C for up to one
year
2400nM Add 1160mL Tris-EDTA to aliquot on
day of use
25mL 600nM
Natural Ligand
T4 1000mM Dissolve 5mg into 6435mL
DMSO in a test tube by gentle
vortex and transfer to storage
vessels
1500mL pp tubes at
20 C for up to three
years
11,000nM Add 11mL stock solution to 989mL
DMSO
70mL (0.5mL T4, 5mL
125I-T4, and 64.5mL
Tris-EDTA per
sample)a
55nM+5%b
125I-T4 0.0536mM
(1000mCi/g)
Transfer contents of ampoule
to storage vessel
1500mL pp tube at 4 C
for up to two months
(use stock)
Competitor Ligand (Select One)
T4 (see above) 20 to
40,960nM
Perform two-fold dilution series
from 40,960 to 20nM using T4 stock
to prepare standards for calibration
curve
5mL 1 to 2048nMc[26_TD$DIFF]
4-OH-BDE-
49
19.9mM Conduct a solvent exchange for
DMSO using nitrogen
evaporator
2000mL amber glass
vials at 4 C for several
years
5 to 5120nM Perform two-fold dilution series
from 5 to 5120nM
5mL 0.125 to
256nMd
Total Volume Per Sample = 100mL
aSee Sample Preparation for details.
bConcentration of 125I-T4 varies depending on decay schedule (see Precautions and tips).
cConcentration range of [27_TD$DIFF]1 to 2048nM for TTR; 1 to 1024nM for ALB.
dConcentration range of 0.25 to 256nM for TTR; 0.125 to 128nM for ALB.
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Fig.1. Example of the sample set up procedure, including vial labels and concentrations of thyroxine (T4) as a competitor ligand
for the calibration exercise.
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the sample to the head of the corresponding column, being careful not to disturb the gel bed.
Release the emptied pipette tip into the incubation tube.2. Repeat for each sample in the replicate set, and centrifuge samples for 4min at 1000 g.
3. Measure the radioactivity of the eluate fraction, as well as the residual radioactivity in the
incubation tubes containing the discarded pipette tips.
Repeat Steps 1 to 3 for each of the remaining replicate sets. The separation procedure involves size
exclusion chromatography, whereby the protein-bound ligand is eluted from the Bio-Spin1 columns
and unbound ligand remains in the columns. The size exclusion limit of the chromatography columns
is 6000 g/mol, and thus any compound smaller than this size will travel through the polyacrylamide
beads (a longer route through the column) while larger molecules will move around the beads (a
shorter route through the column). Measuring the radioactivity of the emptied incubation tubes and
pipette tips accounts for nonspeciﬁc binding and any potential transfer loss.
Note: Previous versions of this method [1,8–10] suggest an additional step involving rinsing of the
columns with Tris buffer, followed by a second round of centrifugation to elute all protein-bound
ligand. This step was found to be unnecessary as the present method is optimized to the sample
volumes and Bio-Spin1 columns used.
Precautions and tips
TTR is a labile substance and is susceptible to denaturation. It is thus important to handle proteins
with care when preparing solutions and processing samples to ensure they remain intact. Do not
vortex solutions containing TTR. Prepare working solutions of TTR or ALB only on the day of use to
ensure that the protein structural integrity is maintained. Additionally, keep solutions containing
proteins on ice during sample preparation and processing also to prevent denaturing. Incubation
mixtures should be left in the fridge until ready for processing, and analyzed quickly so as to reduce
time on the column. Use a temperature controlled centrifuge set to 4 C tomaximize protein integrity.
[(Fig._2)TD$FIG]
Fig. 2. Competitive ligand binding curves for (A) thyroxine (T4)-transthyretin (TTR) interactions with T4 or with the competitor
ligand 4-OH-BDE-49, and (B) T4-albumin (ALB) interactions with T4 or with competitor ligand 4-OH-BDE-49. Results are
presented as relative percent of T4 bound to protein compared to controls (means standard deviations; 6 replicates for each
concentration tested).
K.L. Hill et al. /MethodsX 4 (2017) 404–412 409Furthermore, it is recommended that Eppendorf LoBind1 Polypropylene test tubes be used to prepare
incubation samples, in order tominimize potential loss of proteins and ligands from adsorption to the
vessel.
Care must also be taken when handling radiolabelled [34_TD$DIFF] 4. All components of the assay involving
125I-T4 must be completed in a radioactivity-licensed laboratory by trained personnel. Wear the
necessary personal protective equipment, and work under a fume hood for all steps involving pipette
work. The proportion of 125I-T4 added to samples can be varied depending on signal strength, aiming
for>10,000 cpmper sample for initial readings. Adjust the amount of Tris-EDTA added to each sample
accordingly.
Data analysis
Calculate the percent of protein binding for each sample by dividing the radioactivity of eluate on
Day 2 by the initial radioactivity measured on Day 1, minus any transfer loss (i.e., % binding = eluate
cpm/[Day 1 cpm cpm of emptied incubation tube and pipette tip]). Express results with the
logarithmic competitor concentration on the X-axis, and mean standard deviation of percent
binding compared to controls on the Y-axis (Fig. 2). Generate IC50 estimates in GraphPad Prism 7.02
(GraphPad Software, Inc., La Jolla, CA), using the [inhibitor] vs. response  variable slope equation
(Table 3), deﬁned as:
Y =Bottom+ (TopBottom)/(1 + 10(LogEC50-X)*Hillslope)
The inhibition constant (Ki) for each competitor can be determined based on Cheng and Prusoff (1973)
and following GraphPad guidance [18,19]. In a homologous assay (i.e., with T4 as the competitor) the
cold ligand and radioligand can be assumed to have the same binding afﬁnities. As such, the Ki and the
equilibrium dissociation constant (Kd) for T4 are determined using the IC50 of T4 and the
concentration of radioligand in samples:
(Ki)T4,125I-T4 = (Kd)T4,125I-T4 = (IC50)T4 [125I-T4]
With these parameters deﬁned, the Ki of other competitors can be determined using the following
equation:
(Ki)competitor = (IC50)competitor/(1 + [125I-T4]/(Kd)125I-T4)
A simpliﬁed method for calculating Ki is as follows:
(IC50)T4/(IC50)competitor = (Ki)T4/(Ki)competitor
Table 2
Description of the reagents, materials and equipment required to conduct the thyroid hormone competitive binding assay.
Component Details Source
Reagents
Transthyretin (TTR) Lyophilized from human
plasma (95%)
Sigma-Aldrich P1742
Albumin (ALB) Lyophilized from human
plasma (99%)
Sigma-Aldrich A8763
L-thyroxine (T4) (98%) Sigma-Aldrich T2376
Radio-labeled L-thyroxine (125I-T4) 50mCi (800–1000mCi/g) MP Biomedicals 07190128
40-hydroxy-2,20 ,4,50-tetrabromodiphenyl ether
(4-OH-BDE-49)
10mg/mL in acetonitrile
(97.8%)
Chromatographic Specialties Inc.
AHBDE4002SCN02X
Tris-EDTA buffer solution 10mM Tris–HCL, 1mM EDTA,
pH 8.0
Sigma-Aldrich 93283
Materials
Amber glass vials 2mL with lids Chromspec C779100A
Eppendorf1 LoBind microcentrifuge tubes 1.5mL with attached caps Sigma-Aldrich Z666505
Polypropylene test tubes 1275mm with lids Sigma-Aldrich T1911
Bio-Spin1 P-6 Gel Columns Tris buffer, sample volume 50–
100mL
Bio-Rad 732-6228
Equipment
Eppendorf1 pipettes various sizes with corresponding tips
Nitrogen evaporator
Fridge (4 C) and freezer (20 C)
Temperature controlled centrifuge (4 C)
Gamma counter in radioactivity-licensed laboratory
Analytical balance
410 K.L. Hill et al. /MethodsX 4 (2017) 404–412The relative potency for a competitor is deﬁned as (IC50)T4/(IC50)competitor, and thus the above
calculation can be re-arranged as:
(Ki)competitor = (Ki)T4/(relative potency)competitor
Note that at lowconcentrations of radioligand, the Ki for a competitor approximates the corresponding
IC50, which is the case herein.
Method validation
A method calibration curve should be generated in duplicate each time an assay batch is
performed, using the series of prepared concentrations of the natural ligand as the competitor (e.g.,
4 to 2048nM T4 for TTR, plus negative controls). To ensure instrument performance, the gamma
counter should be calibrated prior to each use, and instrument blanks (i.e., empty test tubes) can be
included at various points during measurement of sample radioactivity. Serving as a positive control,
each assay should include triplicate samples with the IC50 concentration of a known potent
competitor. For example, the IC50 of 4-OH-BDE-49 for TTR is [35_TD$DIFF]12.2 nM (Table 3); other potential
competitor ligands could include 4-OH-CB-187 (CAS 158076-68-7) [9] and tetrabromobisphenol ATable 3
IC50 and Ki values for thyroxine (T4) and 4-OH-BDE-49 competitive binding to the human thyroid hormone transport proteins
transthyretin (TTR) or albumin (ALB).
Competitor T4-TTR T4-ALB
IC50 (nM) Ki IC50 (nM) Ki
T4 91.5 91.2 4.80 4.52
4-OH-BDE-49 12.2 12.2 1.15 1.08
[(Fig._3)TD$FIG]
Fig. 3. Competitive ligand binding curves showing the inter-laboratory reproducibility of thyroxine (T4)-transthyretin (TTR)
calibration for results produced in our NWRC (Ottawa, Canada) laboratory (n = 6) compared to the results produced in the
laboratory at the Vrije Universiteit Amsterdam (Amsterdam, The Netherlands) (n =2). Results are presented as relative percent
of T4 bound to TTR compared to controls (means standard deviations).
K.L. Hill et al. /MethodsX 4 (2017) 404–412 411(TBBPA, CAS [36_TD$DIFF][24_TD$DIFF]79-94-7) [1,8]. Negative controls should also be included for each assay batch, where the
competitive ligand is absent and replaced with only DMSO. An additional method validation test that
can be included in the assay procedure is a test of column performance using a sample prepared as a
negative control but containing Tris-EDTA buffer inplace of TTR.With this control, the ligands are in an
unbound state and therefore should remain in the column after centrifugation, resulting in
background radioactivity in the eluate. All assays should include triplicate samples, and should be
conducted twice on separate days to include inter-and intra-day replicates (n = 6 total). Inter-
laboratory reproducibility of this in vitro assay was conﬁrmed by comparing T4-TTR calibration data
produced in our National Wildlife Research Centre (Ottawa, Canada) laboratory to those produced in
the laboratory of Dr. Timo Hamers (Department of Environment & Health, Vrije Universiteit
Amsterdam, Amsterdam, The Netherlands) (Fig. 3).
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